About
Small Molecules targeting Alzheimer's
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
632
By Phase
PHASE3: 2PHASE2: 1PHASE1: 2
By Status
COMPLETED: 3ACTIVE_NOT_RECRUITING: 2
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06304883Lead Sponsor
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
PHASE3Active, not recruiting
163 participants
Started: Apr 2, 2024 · Completed: Jan 31, 2027
NCT04770220Lead Sponsor
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
PHASE3Completed
325 participants
Started: May 19, 2021 · Completed: Jul 29, 2024
NCT04693520Lead Sponsor
Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease
PHASE2Active, not recruiting
84 participants
Started: Sep 30, 2020 · Completed: Aug 31, 2024
NCT04157712Lead Sponsor
Multiple Ascending Dose Study of ALZ-801
PHASE1Completed
48 participants
Started: Sep 26, 2015 · Completed: Jul 4, 2016
NCT04585347Lead Sponsor
Single Dose Study of ALZ-801 Prototype Tablets
PHASE1Completed
12 participants
Started: Sep 16, 2015 · Completed: Nov 13, 2015
Locations (1)
Headquarters
Framingham, MA, United States
Map
Loading map...